Here are the DEF 14A proxy statements from AYTU BioPharma, Inc. (AYTU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AYTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AYTU filings page.
Aytu BioPharma, Inc. is asking stockholders at its 2027 annual meeting, scheduled for December 10, 2026, to elect five directors and vote on four other proposals: add 500,000 shares to the 2023 Equity Incentive Plan, bringing its reserve to 1,000,000 shares; approve a new 2027 Employee Stock Purchase Plan (ESPP) with 500,000 shares reserved; ratify Grant Thornton as auditor for fiscal 2027; and cast a nonbinding advisory vote on 2026 executive compensation. The board recommends voting for each proposal. Stockholders of record on October 13, 2026, are eligible to vote; 10,868,208 common shares were outstanding that day.
If approved, no ESPP purchase rights may be exercised before stockholder approval, and its first offering period would start on the first trading day on or after July 1, 2027. The proposed ESPP purchase price applies a 15% discount to the lower of the offering-date or purchase-date value. If Proposals 2 and 3 are both approved, the proxy’s table shows fully diluted overhang of 4.1%. Grant Thornton’s audit fees were $705,000 for fiscal 2026, compared with $849,000 for fiscal 2025.
Aytu BioPharma (AYTU) set its 2026 annual meeting for December 10, 2025 at 10:00 a.m. MT in Denver. Stockholders of record at the close of business on October 13, 2025 may vote; 10,188,208 shares of common stock were outstanding and entitled to vote. A quorum requires at least one-third of eligible shares.
Stockholders will vote to elect five directors, ratify Grant Thornton as independent auditor for the fiscal year ending June 30, 2026, and approve, on a non-binding advisory basis, 2026 executive compensation. The Board recommends voting FOR all items. Four of five directors are independent under Nasdaq rules; John A. Donofrio, Jr. serves as Chairman.
Audit fees were $849,000 in fiscal 2025 versus $1,018,000 in fiscal 2024. The Board met 12 times in fiscal 2025; the Audit Committee met six times and the Compensation Committee once. Effective July 1, 2025, non-employee director compensation includes cash retainers and annual grants of 10,000 restricted shares or RSUs. In October 2025, equity awards were granted to executives, including 22,500 restricted shares to the CEO, 17,500 to the CFO, and 12,500 each to the CBO and CCO, vesting over three years.